Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hisun Pharma to Invest $162 Million into its JV with Pfizer

publication date: May 22, 2012
More information surfaced about the financing of the high-profile JV being set up by Zhejiang Hisun Pharma and Pfizer. Hisun will contribute a total of $162.5 million for a 51% stake, implying a value of $318.6 million for the venture. The registered capital, however, is listed as $250 million. Hisun may have put in extra capital to nail down a majority stake, but it probably didn’t offer up an extra $70 million for control. More details...

Stock Symbols: (SHA: 600267) (NYSE: PFE)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital